|1.||Ziegler, Renatus: 6 articles (03/2009 - 10/2006)|
|2.||Büssing, Arndt: 5 articles (01/2012 - 11/2005)|
|3.||Grossarth-Maticek, Ronald: 4 articles (06/2010 - 10/2006)|
|4.||Grossarth-Maticek, R: 3 articles (03/2008 - 05/2001)|
|5.||Zänker, Kurt S: 2 articles (01/2014 - 08/2005)|
|6.||Hanisch, Jürgen: 2 articles (01/2014 - 01/2004)|
|7.||Matthes, Harald: 2 articles (01/2014 - 01/2014)|
|8.||Bock, Paul R: 2 articles (01/2014 - 01/2004)|
|9.||Bar-Sela, Gil: 2 articles (03/2013 - 01/2006)|
|10.||Raak, Christa: 2 articles (01/2012 - 01/2009)|
09/01/1989 - "Mistletoe, or 'iscador' as its homoeopathic preparation is called, has been found beneficial in treating patients with some forms of cancer. "
01/01/1983 - "Studies on the tumor-inhibiting efficacy of Iscador in experimental animal tumors."
08/01/2014 - "This study shows that Iscador(®) can be injected subcutaneously without a risk of worsening of the clinical signs or exacerbation of tumors. "
03/01/2009 - "Only a few controlled clinical trials have been performed with the mistletoe preparation Iscador as a complementary treatment for cancer, many of them with medium to low quality due to methodological shortcomings. "
01/01/2009 - "Future studies evaluating the effects of Iscador should focus on a transparent design and description of endpoints in order to provide greater insight into a treatment often being depreciated as ineffective, but highly valued by cancer patients."
08/01/2004 - "Complementary therapy of patients with primary, non-metastatic breast carcinoma with the mistletoe extract Iscador was safe and in comparison to the control group within the same study cohort showed considerably fewer ADRs attributed to concurrent conventional therapy, reduced disease symptoms, and suggested a significant improvement of survival. "
08/01/2004 - "The purpose of the study was to evaluate the therapeutic efficacy and safety of a long-term complementary therapy of primary, non-metastatic breast carcinoma patients treated with standardized European mistletoe extract Iscador("mistletoe") in addition to the conventional adjuvant oncologic therapy, and compared to the control group treated with the conventional therapy alone. "
01/01/2004 - "The purpose of the study was to evaluate the therapeutic efficacy and safety of long-term complementary therapy in primary, non-metastatic mammary carcinoma patients in UICC stage I-III with a standardized European mistletoe extract (Viscum album L., Iscador, "mistletoe extract") given in addition to conventional adjuvant oncologic therapy (i.e. "
02/01/1979 - "A comparison of the results of the two collectives shows that Iscador a special preparation of viscum album, is a useful and effective treatment of carcinoma of the ovary, particularly since it usually does not cause serious and undesired side effects. "
01/01/1969 - "[Studies on additional Iscador therapy in the management of women with surgically and radiotherapeutically treated genital carcinoma]."
|3.||Neoplasm Metastasis (Metastasis)
08/01/2000 - "Role of natural killer cells in iscador mediated inhibition of metastasis by adoptive immunotherapy."
01/01/1999 - "Inhibition of lung metastasis by adoptive immunotherapy using Iscador."
06/01/2007 - "Psychosomatic self-regulation in the Iscador group improved significantly within 12 months compared with the control group in the randomized as well as in 1 non-randomized study (cervical cancer without metastases): estimate of the median difference and 95% CI: 0.70 (0.15-1.05) and 0.25 (0.15-0.35), respectively. "
03/31/2008 - "The effect of therapy with Iscador within 12 months on psychosomatic self-regulation as a measure of autonomous coping with the disease shows a significant rise in the Iscador group against the control group in the randomized as well as in the non-randomized study on patients with corpus uteri cancer without metastases: estimate of the median difference and 95% confidence interval: 0.40 (0.15, 0.70) and 0.70 (0.25, 1.15) respectively. "
03/31/2008 - "(2) Two non-randomized matched-pairs studies: corpus uteri cancer patients without (103 pairs) and with distant metastases (95 pairs) that already received mistletoe (Iscador) therapy were matched by the same criteria to control patients without Iscador therapy. "
11/26/1999 - "This case report demonstrates the efficacy of treating lymphoma with extract of mistletoe (Iscador). "
04/01/1990 - "Iscador was found to be cytotoxic to animal tumor cells such as Dalton's lymphoma ascites cells (DLA cells) and Ehrlich ascites cells in vitro and inhibited the growth of lung fibroblasts (LB cells), Chinese hamster ovary cells (CHO cells) and human nasopharyngeal carcinoma cells (KB cells) at very low concentrations. "
|5.||Non-Hodgkin Lymphoma (Lymphosarcoma)
08/01/2005 - "Single cases of clinical observations suggest the efficacy of the Viscum album (VA) extract Iscador P in the treatment of follicular B-Non-Hodgkin's Lymphoma (B-NHL). "
08/01/2005 - "The Viscum album extract Iscador P does not cause an autocrine interleukin-6 loop in B-Non-Hodgkin's Lymphoma cell lines."
|1.||viscum album peptide (Iscador)
|8.||Interleukin-6 (Interleukin 6)
|9.||Recombinant Interferon Type I
|10.||Radioactive Fallout (Fallout, Radioactive)
|1.||Drug Therapy (Chemotherapy)
|5.||Heterologous Transplantation (Xenotransplantation)